



# *Michigan Association of Health Plans*

---

## House Committee on Health Policy December 3, 2013

### ***Testimony of Michigan Association of Health Plans in opposition of HB 4751***

#### **PRESIDENT**

Bruce Hill  
*HealthPlus of Michigan*

#### **PRESIDENT-ELECT**

Beverly A. Allen  
*CoventryCares of Michigan/Aetna*

#### **SECRETARY**

Jon Cotton  
*Meridian Health Plan of Michigan*

#### **TREASURER**

Randy Narowitz  
*Total Health Care*

#### **EXECUTIVE COMMITTEE MEMBERS-AT-LARGE**

Kathy Kendall  
*McLaren Health Plan*

Kimberly Thomas  
*Priority Health*

#### **BOARD MEMBERS**

James Connelly  
*Health Alliance Plan*

Carrie Harris-Muller  
*ProCare Health Plan*

Stephan Harris  
*Molina Healthcare of Michigan*

John Randolph  
*Paramount Care of Michigan*

Mark Saffer  
*Midwest Health Plan*

Don Schmidt  
*UnitedHealthcare Community Plan, Inc.*

Pamela Silva  
*Grand Valley Health Plan*

Dennis Smith  
*Upper Peninsula Health Plan*

Scott Wilkerson  
*Physicians Health Plan*

#### **EXECUTIVE DIRECTOR**

Richard B. Murdock  
*Michigan Association of Health Plans*

Good morning Madam Chair and members of the committee, my name is Christine Shearer, Deputy Director, of Legislation and Advocacy for the Michigan Association of Health Plans. With me today is Dr. Vanita Pindolia, VP Ambulatory Clinical Pharmacy Programs, Health Alliance Plan and Dave Bilardello, Executive Director, Public Policy, Priority Health, who has a background in underwriting.

As many of you already know, we are opposed to House Bill 4751. However, we don't want anyone to misinterpret our position as one of insensitivity. I bet if we asked everyone in this room to raise their hands if they personally (either themselves or a loved one) have been impacted by cancer, we would have an overwhelming demonstration that illustrates the scope and prevalence of this disease.

As health plans, we understand the physical, emotional and financial toll that cancer can have on people. That is why we provide coverage for all FDA-approved antineoplastic drugs – including the oral chemotherapy treatments that are the focus of House Bill 4751. That's also why we encourage, financially incentivize and, at times, require members to pursue healthy behaviors, seek preventive care and see their doctor for regular checkups and screenings. In other words, we are just as focused on preventing cancer as we are to treating it.

The purpose of our testimony is not questioning the benefits or efficacy of orally-administered chemotherapy treatments. Instead, we hope to provide some background on high-cost specialty drugs and the unintended consequences that may result if House Bill 4751 were effectuated into law.

Oral enzyme targeted chemotherapy is significantly more expensive than traditional intravenous treatment. Oral enzyme-targeted chemotherapy medications cost as much as \$10,000 per month. Co-pays and other forms of cost sharing are substantially higher for oral chemotherapy to account for the high cost of these medications. Unlike traditional intravenous treatment, which is considered an established medical benefit, oral chemotherapy is reimbursed under the specialty prescription benefit tier. Specialty pharmaceuticals, targeted to small populations of the public, are among the most expensive pharmaceuticals in the market, contributing to explosive growth in costs that is making health care more expensive for everyone.

Cost sharing is a crucial part of controlling health care costs, whether it is to mitigate overutilization of prescription drugs (traditionally done to decrease inappropriate use of high cost brand drugs) OR offset the expense of costly prescription drugs (outcome of specialty drugs entering the market at \$50,000-\$80,000+/patient/year). Establishing an arbitrary cost sharing limit for those who are using these expensive medications means more of the cost for oral chemotherapy medication will need to be borne by the other enrollees and insured in the form of higher premiums and/or higher out-of-pocket cost for other services.

I will now turn it over to Dr. Vanita Pindolia.

Proponents of House Bill 4751 would like to make this about the disparity between IV-administered and orally-administered cancer treatments. Biologic drugs are cutting edge medicines used by a number of patients for chronic conditions such as cancer, multiple sclerosis, rheumatoid arthritis, HIV/AIDS, epilepsy and hepatitis. Why is cancer the only disease that is under consideration in HB 4751? They can be vastly more expensive than traditional agents I will highlight how HB 4751 actually creates and/or exacerbates any disparity. Ms. Shearer asked me to address committee members concerns that have been raised thus far through previous testimony and meetings, including;

1. What is the definition of a specialty Drug?
2. Why are specialty drugs so expensive?
3. Are there generic alternatives?
4. What percentage of drugs in the pipeline will be specialty drugs?
5. What kind of copay assistance is available for patients receiving specialty drugs?
6. What patient population would NOT be affected by this bill; thus continue to pay specialty drug copays/co-insurances?

Oral chemotherapy medications that have an equivalent intravenous (iv) formulation can be interchanged and used in the same manner. This involves taking the pill for a few days and then being off of them for a few days (normally) and then this gets repeated every 2-4 weeks. Each time it gets repeated it is called a cycle of treatment. Cancer treatment requiring chemotherapy includes a set number of cycles (e.g. 6 cycles or 6 courses of chemotherapy) and then chemotherapy treatment ends. Whether the oral or equivalent iv formulation is used, there is a set end date. Examples of these types of oral chemotherapy agents include: Xeloda and Temodar.

Another type of oral chemotherapy medications include the biologics (commonly associated with tyrosine kinase inhibition). These oral chemotherapy agents do NOT have an equivalent IV formulation available. Unlike traditional chemotherapy, these agents need to be taken daily for life or until resistance occurs. With these drugs, the patient basically lives with cancer cells kept at bay through enzyme inhibition vs with traditional chemotherapy actually killing the cancer cells. These oral biologic chemotherapy agents have turned cancer treatment into a type of chronic disease treatment. Oncologists in the past never had to worry about unknown non-adherence to therapy – the patients came in every 2-4 weeks for each cycle of treatment and follow-up care in between, as needed. With the oral biologic chemotherapy treatment, patients can go months in between

oncologist appointments and previously unknown non-adherence to therapy, as seen with other chronic diseases, appeared with cancer care. Therefore, treatment and management of patients with oral biologic chemotherapy is more like treatment and management of patients with chronic disease.

Basically oral biologic chemo agents are not used in the same manner as the IV chemotherapy agents.

Oral biologic chemo agents administered daily for life. IV chemotherapy agents given only for a few days every 2-4 weeks for a certain number of cycles. As you can see in our attached Chart the prices can vary tremendously between oral and IV drug treatments. (review chart)

I will now turn it over to Dave Bilardello.

Passing HB 4751 will have the potential to help less than 1/10<sup>th</sup> of 1% of Michigan citizens. In Michigan 53% of all cancer diagnosis are to those over 65 years of age, and covered by Medicare. Of those remaining, only 35% of those could have the potential to be affected by this legislation. When we remove those covered by ERISA plans, Medicaid and the uninsured, this equates to 0.09% of Michigan population. In doing so would provide an unfair competitive advantage for non-MAHP members. Furthermore, surveying members and reporting the result could certainly be considered a violation of state and federal antitrust laws.

Let's review the Milliman study – which estimates that premiums will increase \$0.05 to \$1.00 PMPM – that way we are not totally dodging the cost question. However, if we do use the Milliman study, we'll want to point out some of the limitations, including:

- a. The Milliman analysis was distributed two months **before** the PPACA was enacted into law. As such, it didn't take account for the AV requirements, OOP maximum and cost-sharing credits now available.
- b. Biologic specialty drugs represent 50% of the forthcoming drugs that are expected to hit the market in the next few years. Of those, almost half are cancer treatments. The Milliman study did somewhat recognize this trend. However, it did not quantify, factor nor forecast how the increased treatment introductions will impact the PMPM cost as these medications are released into the market.
- c. The Milliman study did not consider the effects of additional specialty drugs being classified under the medical benefit for non-cancer disease states. While that is outside the scope of HB 4751, such legislative initiatives will undoubtedly be introduced, considered and possibly effectuated if HB 4751 is signed into law. In other words, the intent of HB 4751 is to standardize cost-sharing for chemotherapy treatments. However, doing so will create a whole new disparity – one that could prove to be much, much costlier if addressed in the same manner.

As stated earlier "Michigan is unique" and in keeping with that premise, maybe we should commission our own actuarial study that considers the current regulatory requirements to adopt best practices that result in better patient outcomes in a cost-effective manner and use actual Michigan benefit designs that are offered on the federal Marketplace?

The PPACA includes provisions that are set to effectuate as early as January 1, 2014 that will provide new/enhanced benefits and cost reductions/protections. Thus this bill is unnecessary

because the ACA already sets out of pocket limits for consumers, which apply for all prescription and medical out-of-pocket costs combined.

- a. OOP expenses will be capped at \$6,350/individual and \$12,700/family for all plans in all markets

Lowering cost sharing for oral chemotherapy affects the actuarial value under the ACA. Between the comprehensive essential health benefits package and restrictions on benefit limits, it is proving extremely difficult to meet the actuarial value requirements for these new plans. Limiting cost sharing for oral chemotherapy exacerbates the problem. In order to keep the actuarial value in balance, there will need to be an adjustment made to some other type of cost sharing in the benefit design.

- b. Cost-sharing credits will have the effect of increasing the actuarial value and limiting the OOP expenses for those who need it most – individuals and families making 250% or less than the federal poverty level

The bottom line is:

- Health plans ALREADY cover these medications and treatments to help patients battle cancer.
- Chemotherapy drugs are expensive and oral chemotherapy drugs are very expensive compared to IV treatment.
- Chemo treatments are covered in different ways depending on where it's received
- This bill could actually result in patients paying more out-of-pocket
- Regardless of the intent of the bill an unintended consequence would be to place upward pressure on premiums.

Christine Shearer

Health insurance plans have taken important steps over the last decade to address the critical issues of increasing access to innovative, quality health care products and cost control mechanisms that would better allow individuals and small businesses to obtain coverage in the private market. The adoption of benefit mandates that do not promote evidence-based medicine may lead to lower quality of care, over-utilization, and high costs for possibly non-effective treatments. HB 4751 threatens the efforts of all healthcare stakeholders to provide consumers with meaningful health care choices and affordable coverage options.

MAHP believes this bill doesn't solve the problem but it shifts the problem and it shifts it to the employer and individual premiums.

For these reasons, MAHP respectfully opposes HB 4571.

Thank you for the opportunity to testify. We are happy to answer any questions.

## Manufacturer Co-pay Card Programs

<u>Disease State</u>	<u>Medication Name</u>	<u>Co-pay Card Program</u>	<u>Website</u>	<u>Maximum Benefit</u>	<u>Program/Re-apply Duration</u>	<u>Some Private/Commercial Insurance Coverage Needed</u>	<u>Gov't Ins Eligibility</u>
Rheumatoid Arthritis	Actemra	Actemra Co-Pay Card Program	Actemra CoPay Card Program	Up to \$3,500/year	Every 12 Months	YES	NO
Kidney Cancer	Afinitor	Afinitor Co-Pay Card	Afinitor CoPay Assistance Program	Up to \$1,200/month	Every 12 Months	YES	NO
Breast Cancer	Aromasin	Aromasin Co-Pay Card Program *Patient must get card from office or call themselves	Aromasin Co-Pay Card Program	Pay no more than \$4/month (up to \$125 savings/month)	Every 12 Months	YES	NO
HIV	Atripla	Atripla Co-pay Assistance Program	Bristol-Myers Squibb Co-Pay Assist (Atripla)	Pay as low as \$0.00/month	Every 12 Months	YES	NO
Colon Cancer OR Brain Cancer	Avastin	Avastin Co-Pay Card	Avastin Copay Card First Month Free Application and/or *\$10/month	80% of copay/up to \$4,000/year One free 30 day Trial and pay no more than \$10/month	Every 12 Months	YES	NO
Multiple Sclerosis	Avonex	Avonex Copay Card Program	Baraclude Co-pay Benefit Program	Up to \$400/month \$1200/month for 90 day supply	One time Offer per PT	YES	NO
Hepatitis B	Baraclude	Baraclude Co-pay Benefit Program	Benlysta Copay Card Program	*Pay \$0.00/month	Every 12 Months	YES	NO
SLE or Lupus	Benlysta	Benlysta Co-pay Card BetaPlus Program	BetaPlus Program Cimplicity Savings Card	**\$0 Copay if Eligible	Every 12 Months	YES	NO
Multiple Sclerosis	Betaseron	Betaseron BetaPlus Program	Gilead Co-Pay Program	N/A	Up to 17 Fills	NO	NO
Rheumatoid Arthritis	Cimzia	Cimplicity Savings Card	Gilead Co-Pay Coupon Card	*Up to \$400 off/month	Every 12 Months	YES	NO
HIV	Complera	Gilead Co-Pay Program	Copaxone Co-Pay Solutions Card	Up to \$2,500/month, \$12,000/year, *Patient responsible for \$35/month	Every 12 Months	YES	NO
Multiple Sclerosis	Copaxone	Copaxone Co-pay Solutions	Egrifta Copay Program	Up to \$200 off per month	Every 12 Months	YES	NO
HIV	Egrifta	Egrifta Copay Program					

## Manufacturer Co-pay Card Programs

<u>Disease State</u>	<u>Medication Name</u>	<u>Co-pay Card Program</u>	<u>Website</u>	<u>Maximum Benefit</u>	<u>Program/Re-apply Duration</u>	<u>Some Private/Commercial Insurance Coverage Needed</u>	<u>Gov't Ins Eligibility</u>
Rheumatoid Arthritis	Enbrel	Enbrel Support Card	Enbrel Copay Support Card	*Up to \$4000/Year	Every 12 Months	YES	NO
Metastatic Basal Cell Carcinoma	Erivedge	Erivedge Co-Pay Card	Erivedge Oncology Copay Card	80% of copay/up to \$4,000/Year	Every 12 Months	YES	NO
Chronic Iron Overload	Exjade	Exjade Co-Pay Card	Exjade Copay Assistance Program	*Up to \$100/Month	Every 12 Months	YES	NO
Multiple Sclerosis Breakthrough Cancer Pain	Extavia	Extavia Co-Pay Assistance Program	Extavia CoPay Assistance Program	Up to \$7,200/Year	Every 12 Months	YES	NO
Postmenopausal Women with Estrogen-receptor positive tumor(s)	Fareston	Fareston Co-pay Assistance Program	Fareston Co-pay Card	Up to \$100 for three Months	Every 12 Months	YES	NO
Hereditary Angiodema	Firazyr	Firazyr Co-pay Assistance Program	Firazyr Co-pay Card	Pay no more than \$30/month (max of \$200 assistance per month)	Every 12 Months	YES	NO
Multiple Sclerosis GIST (for CML promoting Tasigna)	Gilenya	Gilenya GO Program	Gilenya GO Program	*Up to \$9500/year in assistance *\$30.00 copay each month if approved.	When patient changes SP	YES	NO
Infertility	Gleevec	Gleevec Co-pay Program	MyCircle Co-pay Program	*Pay \$0.00/month	Every 12 Months	YES	NO
Breast Cancer	Gonal-F	Gonal-F Copay Card	Gonal F Copay Card Program	*Up to \$200/Month off	Every 12 Months	YES	NO
Rheumatoid Arthritis	Herceptin	Bio-Oncology Co-Pay Card	Herceptin CoPay Card Program	80% of copay/up to \$4,000/Year	Every 12 Months	YES	NO
Hepatitis C	Humira	Humira Protection Plan	Humira CoPay Card Program	**No more than \$5/Month	Over the course of Treatment (up to 1 year)	YES	NO
	Incivek	Incivek Copay Assistance Program	Incivek Savings Card	\$10,000 over course of treatment	YES	NO	NO

## Manufacturer Co-pay Card Programs

<u>Disease State</u>	<u>Medication Name</u>	<u>Co-pay Card Program</u>	<u>Website</u>	<u>Maximum Benefit</u>	<u>Program/Re-apply Duration</u>	<u>Some Private/Commercial Insurance Coverage Needed</u>	<u>Gov't Ins Eligibility</u>
Resistant CML or Philadelphia chromosome positive acute lymphoblastic leukemia	Iclusig	Ariad PASS Co-pay Assistance Program	Inclisig Co-pay Card Program	N/a	Every 12 Months	YES	NO
Myelofibrosis	Jakafi	Jakafi Co-pay Program	Jakafi Co-pay Program Application	**\$0 Copay if Eligible (Turnaround time: 48 hours)	Every 12 Months	YES	NO
Metastatic Breast Cancer	Kadcyla	Kadcyla Co-pay Program	Kadcyla Co-pay Program	Pay 20% of original co-pay/no more than \$100*	Every 12 Months	YES	NO
HIV	Kaletra	Kaletra Co-pay Assistance Program	KALETRA Co-Pay Card	As low as \$0.00/month*	Every 12 Months	YES	NO
Cystic Fibrosis Breakthrough Cancer Pain	Kalydeco	Kalydeco Co-pay Program	Kalydeco Assistance Program	*Pay \$0.00/month	Every 12 Months	YES	NO
Lupron-Depot OR Generic Equivalent	Lazanda	Lazanda Co-Pay Savings Card	Lazanda Co-Pay Savings Program	*Up to \$100 off per month	Every 12 Months	YES	NO
Prostate Cancer Transplant (Organ)	Lupron-Depot Get-Back Program	Lupron-Depot Get-Back Program	Lupron-Depot Get-Back Program	Up to \$125/Month or \$250/3Months	Every 12 Months	YES	NO
Neutrophilis Supplement Liver/Kidney Cancer	Myfortic	Novartis Copay Assistance Program	Myfortic (Novartis) Co-pay Program	As low as \$0.00/month*	Every 12 Months	YES	NO
Platelets Supplement Chronic Pain	Neulasta	Neulasta Copay Card Program	Amgen First Step Program	*As low as \$0 Copay	Every 12 Months	YES	NO
Growth Hormone Deficiency	Nexavar	NexCCAP Program	NexCCAP Program	Up to \$100 off each Rx	Every 12 Months	YES	NO
	Nplate	Nplate Copy Card Program	Amgen First Step Program	*As low as \$0 Copay	Every 12 Months	YES	NO
	Nucynta	Nucynta Patient Savings Card	Nucynta Savings Card	*Pay no more than \$25/Month	Every 12 Months	YES	NO
	Nutropin	Nutropin Copay Card	Nutropin Copay Card Program	\$1500/year or Up to \$4000/year* (eligibility requirements must be met)	Every 12 Months	YES	NO

## Manufacturer Co-pay Card Programs

<u>Disease State</u>	<u>Medication Name</u>	<u>Co-pay Card Program</u>	<u>Website</u>	<u>Maximum Benefit</u>	<u>Program/Re-apply Duration</u>	<u>Some Private/Commercial Insurance Coverage Needed</u>	<u>Gov't Ins Eligibility</u>
Rheumatoid Arthritis	Orencia	Orencia Co-pay Program	Orencia Copay Assistance Card	Up to \$8000/Year	Depends on amount of medication infused per infusion (patient mail in rebate only)	Over the course of Treatment	YES NO
Infertility	Ovidrel	Ovidrel Mail-in Copay Rebate Program	Ovidrel Mail-in Rebate Program	Up to \$200/Month, \$2400/Year	Every 12 Months	YES	NO
Hepatitis C	Pegasys	Pegasys Co-pay Card Program	Pegasys Copay Card Program	Up to \$200/Month	Every 12 Months	YES	NO
Hepatitis C	PEG-Intron	Peg-Intron Rx Co-pay Assistance Program	PEG-Intron Copay Card Program	Up to \$200/Month	Every 12 Months	YES	NO
Metastatic Breast Cancer	Perjeta	Perjeta Co-pay Program	Perjeta Co-pay Card Program	Up to \$200/Month	Every 12 Months	YES	NO
Multiple Myeloma/MDS	Pomalyst	Celgene Patient Support	RevAssist Copay Relief Program	Pay 20% of original co-pay/no more than \$100*	Every 12 Months	YES	NO
Transplant (Organ)	Prograf	Prograf Co-pay Card	Prograf Co-pay Program	*Pay no more than \$25.00/month.	Every 12 Months	NO	NO
ADT	Prolia	Prolia Co-pay Card Program	Prolia Co-pay Assistance Card	As low as \$0.00/month*	Every 12 Months	YES	YES
Multiple Sclerosis	Rebif	Rebif Copay Assistance Card	Prolia Co-pay Card Rebif Copay Assistance	Pharmacy can call and obtain co-pay card	Every 12 Months	YES	NO
Rheumatoid Arthritis	Remicade	RemiStart Program	RemiStart Copay Assistance Card	*As low as \$0.00/Month	Every 12 Months	NO	NO
Multiple Myeloma/MDS	Revlimid	Revassist	RevAssist Copay Relief Program	12 Months/8 Infusions or \$4,400/Year	Every 12 Months	YES	NO
HIV	Reyataz	Reyataz Co-pay Assistance Program	Bristol-Myers Squibb Co-Pay Assist.(Reyataz)	*Pay no more than \$25.00/month.	Every 12 Months	NO	YES
Hepatitis C	Ribasphere RibaPak	RibaPak Copay Savings Card	RibaPak Savings Card	Pay as low as \$0.00/month	Every 12 Months	YES	NO
Non-Hodgkin's Lymphoma	Rituxan	Rituxan Experience Co-Pay Card Program	Rituxan Genentech Copay Card	Up to \$65 off/Month 80% of copay/up to \$4,000/Year	Every 12 Months	YES	NO

## Manufacturer Co-pay Card Programs

<u>Disease State</u>	<u>Medication Name</u>	<u>Co-pay Card Program</u>	<u>Website</u>	<u>Maximum Benefit</u>	<u>Program/Re-apply Duration</u>	<u>Some Private/Commercial Insurance Coverage Needed</u>	<u>Gov't Ins Eligibility</u>
Chemotherapy induced nausea and vomiting	Sancuso	Sancuso Co-pay Assistance Program	Sancuso Co-pay Card Program	Pay no more than \$30/month (max of \$200 assistance per month)	Every 12 Months	YES	NO
Rheumatoid Arthritis	Simponi	Simponi Co-Pay Card	Simponi CoPay Card Program	Up to \$6,000/Year	Every 12 Months	YES	NO
Chronic Myeloid Leukemia	Sprycel	Sprycel-ONE	SPRYCEL Support Program	*Up to \$100/Month	Every 12 Months	YES	NO
Plaque Psoriasis	Stelara	Stelara Support Instant Savings Card	Stelara CoPay Card Program	First 3 doses free then Up to \$10,000/Year on doses 4-6	Every 12 Months	YES	NO
Colorectal Cancer	Stivarga	Stivarga Co-pay Card Program	Stivarga Co-pay Card	\$0.00/month	Every 12 Months	YES	NO
HIV	Stribild	Gilead Copay Card Program	Gilead Co-Pay Coupon Card	*Up to \$400 off/month	Every 12 Months	YES	NO
HIV	Sustiva	Sustiva Co-pay Assistance Program	Bristol-Myers Squibb Co-Pay Assist (Sustiva) Sutent Copay Card Program	Pay as low as \$0.00/month	Every 12 Months	YES	NO
Kidney/GIST/Pancreatic Cancer	Sutent	Sutent Copay Card		*Up to \$5000/year	Every 12 Months	YES	NO
RSV	Synagis	Synagis Co-pay Card	Synagis Co-pay Card Program	Patient pays first \$30 each rx. *Up to \$2,000/Year Covered login:pharmadvantage password: synagis	Every 12 Months	YES	NO
Non-Small Cell Lung Cancer	Tarceva	Tarceva Genentech Co-pay Card Program	Tarceva CoPay Card Program	80% of copay/up to \$4,000/Year	Every 12 Months	YES	NO
Philadelphia Chromosome Positive Chronic Myeloid Leukemia	Tasigna	Tasigna Co-Pay Card	Tasigna Copay Assistance Program				
Multiple Sclerosis	Tecfidera	Tecfidera Co-pay Program	Tecfidera Copay Program	Up to \$150/Month Eligible patients pay no more than \$10/month*	Every 12 Months	YES	NO

## Manufacturer Co-pay Card Programs

<u>Disease State</u>	<u>Medication Name</u>	<u>Co-pay Card Program</u>	<u>Website</u>	<u>Maximum Benefit</u>	<u>Program/Re-apply Duration</u>	<u>Some Private/Commerical Insurance Coverage Needed</u>	<u>Gov't Ins Eligibility</u>
Brain Cancer (Glioblastoma)	Temodar	Temodar Co-pay program	Temodar Copay Program	*As low as \$0.00/Month (must provide estimated yearly household income)	Every 12 Months	YES	NO
Multiple Myeloma/MDS	Thalomid	Celgene Patient Support	RevAssist Copay Relief Program	*Pay no more than \$25.00/month.	Every 12 Months	NO	YES
HIV	Truvada	Gilead Copay Card Program	TRUVADA® Co-Pay Assistance	*Up to \$400 off/month	Every 12 Months	NO	YES
Transplant (Organ)	Valcyte	Valcyte Copay Card	Valcyte Co-pay Assistance Program	n/a	Every 12 Months	YES	NO
Hepatitis C	Victrelis	Victrelis Copay Savings Card	Victrelis Copay Savings Program	*Up to \$200/Month off	Every 12 Months	YES	NO
Opioid Dependence	Vivitrol	Vivitrol Co-pay Card	Vivitrol Co-pay Program	As low as \$0.00/month	Every 12 Months	YES	NO
Hepatitis B (HBV)	Viread	My Access Viread Copay Card	VIREAD Co-pay Program	*Save up to \$200/month	Every 12 Months	YES	NO
Non-Small Cell Lung Cancer	Xalkori	Xalkori Copay Savings Card	Xalkori Copay Program	\$24,000/Year	Every 12 Months	YES	NO
Colon Cancer OR Breast Cancer	Xeloda	Genentech BioOncology Co-pay Card Program	Xeloda CoPay Card Program	80% of copay/Up to \$4,000/Year	Every 12 Months	YES	NO
Rheumatoid Arthritis	Xeljanz	Xeljanz Co-pay Card Program	Xeljanz Co-pay Card Program	*As low as \$0 Copay/month	Every 12 Months	YES	NO
Prevention of Skeletal Related Events	Xgeva	Amgen First Step Program	Amgen First Step Program	*As low as \$0 Copay	Every 12 Months	YES	NO
Severe Persistent Allergic Asthma	Xolair	Xolair Co-Pay Card	Xolair CoPay Card Program	Up to \$4,000/Year (pharmacy can call, enroll patient and obtain card info)	Every 12 Months	YES	NO
Prostate Cancer	Xtandi	Xtandi Patient Savings Program	Xtandi Copay Card Program	*Up to \$1500/month or \$12,000/year	Every 12 Months	YES	NO
Skin Cancer (Melanoma)	Yervoy	Yervoy Copay Assistance Program	Yervoy Copay Program	Patient pays first \$50 each rx. *Up to \$5,000/Year Covered	Every 12 Months	YES	NO

## **Manufacturer Co-pay Card Programs**